The opening of our Boston office again affirms our commitment to enhance the value of our Company by improving our visibility and exposure in the U.S. market. Management believes the Company has reached an important inflection point in its growth that requires the Company to open itself up to the larger, and more life science‐focused, U.S. market
“I’m thrilled to be heading up our Boston office and spearheading several key functions out of this site, including public and investor relations, corporate and business development and clinical operations. The Boston area is the leading biotechnology and life sciences hub in the world and offers innovative biotech companies such as ours access to world-class talent, investors and collaboration partners.” - Alison Silva, President.
“Gaining a foothold in the U.S. has been a strategic objective of ours and part of my vision for the Company. Obtaining our listing on the OTCQB back in June of 2014 to enable investments from American investors, was the first step to improving our visibility and exposure in the U.S. Since then we have been introduced to, and established relationships with, many industry leaders and life sciences investors. I believe that with the opening of our Boston office we are very well poised to build and expand these relationships as we rapidly advance our clinical programs.” – Dr. Wayne Danter, Chief Executive Officer.
On June 16, 2014, the Company commenced trading in the United States on the OTC Markets OTCQB trading platform for venture companies under the symbol COTQF. The OTCQB platform has enabled U.S.‐based investors to obtain information about the Company and invest through a trading platform familiar to them.